Five things to know:
1. Quarterly sales rose 4.7% year over year.
2. Medtronic’s cranial and spinal technologies segment saw $1.2 billion in quarterly sales, an increase of 6.7% year over year.
3. The company’s full neuroscience portfolio saw $2.3 billion in sales, up 4.8% year over year.
4. Medtronic’s medical surgical portfolio grew 3.9% year over year with $2.1 billion in sales. The cardiovascular portfolio netted $2.9 billion in sales, a 6.1% increase year over year.
5. Medtronic raised its guidance for fiscal year 2024 and expects to see full-year growth of 4.75% to 5% year over year.
